share_log

Morgan Stanley Maintains Overweight on Maravai LifeSciences, Lowers Price Target to $11

Benzinga ·  Nov 9, 2023 09:26

Morgan Stanley analyst Tejas Savant maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and lowers the price target from $12 to $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment